| Noninvasive assessment of reperfusion therapy: slow progress towards a worthwhile goal. | |
| | |
MedLine Citation:
|
PMID: 14597920 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
|
Authors:
|
James A de Lemos; David A Morrow |
Publication Detail:
|
Type: Comment; Editorial; Evaluation Studies |
Journal Detail:
|
Title: American heart journal Volume: 146 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2003 Nov |
Date Detail:
|
Created Date: 2003-11-04 Completed Date: 2004-02-25 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 747-9 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Arrhythmias, Cardiac
/
blood,
diagnosis,
etiology,
prevention & control* Biological Markers / blood Creatine Kinase / blood Electrocardiography Fibrinolytic Agents / therapeutic use* Humans Myocardial Reperfusion / adverse effects, methods* Myoglobin / blood Vascular Patency |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Fibrinolytic Agents; 0/Myoglobin; EC 2.7.3.2/Creatine Kinase |
| Comments/Corrections | |
Comment On:
|
Am Heart J. 2003 Nov;146(5):757-63
[PMID:
14597923
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: DHA-rich phospholipids optimize G-Protein-coupled signaling.
Next Document: "Mirror-lake" serial relationship of electrocardiographic and biochemical indices for the detection ...